[Lambert-Eaton myasthenic syndrome]

Area of Science:

• Neurology
• Immunology
• Oncology

Context:

• Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune neuromuscular junction disorder.
• Approximately 60% of LEMS patients have an associated tumor, predominantly small cell lung cancer (SCLC).
• Clinical presentation includes proximal muscle weakness and dysautonomia, with cerebellar dysfunction in less than 10%.

Purpose:

• To describe the clinical characteristics, diagnosis, and management of Lambert-Eaton myasthenic syndrome.
• To explore the association between LEMS, small cell lung cancer, and paraneoplastic cerebellar degeneration (PCD-LEMS).
• To investigate the pathomechanism involving autoantibodies against P/Q-type voltage-gated calcium channels (P/Q-VGCCs).

Summary:

• Diagnosis is confirmed by specific autoantibodies (anti-P/Q-VGCC) and electrophysiological findings (reduced compound muscle action potential amplitude with characteristic increment).
• Pathomechanism involves impaired neuromuscular transmission due to autoantibodies against P/Q-VGCCs, with evidence of reduced P/Q-VGCCs in PCD-LEMS cerebellum.
• Treatment focuses on tumor removal, symptomatic management with 3,4-diaminopyridine and pyridostigmine, and immunosuppressive therapies like IVIg, plasmapheresis, or prednisone.

Impact:

• Effective tumor therapy and LEMS treatment can significantly improve neurological deficits.
• Understanding the role of P/Q-VGCC antibodies may lead to targeted therapies for LEMS and associated neurological syndromes.
• This study highlights the importance of oncological screening and multidisciplinary management for LEMS patients.